Tenaya Therapeutics (NASDAQ: TNYA) stock performance over the year has reflected the typical volatility associated with clinical-stage biotechnology equities, reacting sharply to pipeline clinical trial updates, regulatory feedback, and broader macro-biotech sector sentiment. Financial markets track its equity based on developmental milestones achieved across its cardiac gene therapy pipelines, cash runway burn rates, and ongoing institutional research coverage.